The relative importance of NADPH:: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

被引:38
作者
Saunders, MP
Jaffar, M
Patterson, AV
Nolan, J
Naylor, MA
Phillips, RM
Harris, AL
Stratford, IJ
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Mt Vernon Hosp, Gray Lab, Canc Res Trust, Northwood HA6 2JR, Middx, England
[3] Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England
[4] John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England
基金
英国医学研究理事会;
关键词
cytochrome P450 reductase; indolequinone bioreductive drugs; EO9; transfected P450R;
D O I
10.1016/S0006-2952(99)00405-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Analogues of EO9 (3-hydroxymethyl-5 -aziridinyl-1 -methyl-2[1H -indole-4-7-dione]prop-2-en-1-1-ol) which lack functionality at either the C-2 or C-3 position were synthesised. The aim was to establish the importance of each group towards toxicity and to give an indication as to whether substitution at either posit-ion altered activation and toxicity after metabolism by cellular NADPH: cytochrome c (P450) reductase (P450R). MDA231 breast cancer cells were transfected with the cDNA for human P450R and stable clones were isolated. These high P450R-expressing clones were used to determine the aerobic and hypoxic toxicity of EO9 and the two analogues that lacked functionality at either C-2 or C-3. The results showed that P450R was strongly implicated in the bioactivation of EO9 and its analogues under both of these conditions. This data also showed that the C-3 functionality was primarily implicated in hypoxic toxicity. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:993 / 996
页数:4
相关论文
共 16 条
  • [1] STRUCTURE-ACTIVITY-RELATIONSHIPS FOR DT-DIAPHORASE REDUCTION OF HYPOXIC CELL DIRECTED AGENTS - INDOLOQUINONES AND DIAZIRIDINYL BENZOQUINONES
    BAILEY, SM
    SUGGETT, N
    WALTON, MI
    WORKMAN, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (04): : 649 - 653
  • [2] BAILEY SM, 1994, P AM ASSOC CANC RES, V25, P384
  • [3] BAILEY SM, 1994, BR J CANCER S21, V69, P57
  • [4] CYCLOPROPAMITOSENES, NOVEL BIOREDUCTIVE ANTICANCER AGENTS - SYNTHESIS, ELECTROCHEMISTRY, AND BIOLOGICAL-ACTIVITY OF 7-SUBSTITUTED CYCLOPROPAMITOSENES AND RELATED INDOLEQUINONES
    COTTERILL, AS
    MOODY, CJ
    MORTIMER, RJ
    NORTON, CL
    OSULLIVAN, N
    STEPHENS, MA
    STRADIOTTO, NR
    SWANN, E
    STRATFORD, IJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (22) : 3834 - 3843
  • [5] Franck R. W., 1990, CHEM ANTITUMOR AGENT, P379
  • [6] Hypoxia and radiation response in human tumors
    Hockel, M
    Schlenger, K
    Mitze, M
    Schaffer, U
    Vaupel, P
    [J]. SEMINARS IN RADIATION ONCOLOGY, 1996, 6 (01) : 3 - 9
  • [7] Jaffar M, 1998, ANTI-CANCER DRUG DES, V13, P105
  • [8] Jaffar M, 1998, ANTI-CANCER DRUG DES, V13, P593
  • [9] 2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo
    Naylor, MA
    Jaffar, M
    Nolan, J
    Stephens, MA
    Butler, S
    Patel, KB
    Everett, SA
    Adams, GE
    Stratford, IJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (15) : 2335 - 2346
  • [10] MITOMYCIN ANALOGS .1. INDOLOQUINONES AS (POTENTIAL) BISALKYLATING AGENTS
    OOSTVEEN, EA
    SPECKAMP, WN
    [J]. TETRAHEDRON, 1987, 43 (01) : 255 - 262